US Stock Market Move | Q3 turned profitable, sharply raised full-year revenue guidance, Moderna (MRNA.US) rose over 5%.

On Friday, Moderna (MRNA.US) rose over 5% to $254.36. On the news front, Moderna reported its third-quarter 2026 results. The financial report shows that the company's total revenue was $1.313 billion, up 29% year-over-year, far exceeding the market expectation of about $885 million; net income was $162 million, swinging to a profit from a net loss of $200 million in the same period last year; diluted earnings per share were $0.38, significantly better than the market expectation of a loss of $1.25 per share. The company raised its full-year guidance, sharply increasing its 2026 revenue growth rate from the previous "at most 10%" to 15%25%, and expects about half of revenue to come from the United States and half from international markets; R&D expense guidance was lowered from about $2.9 billion to about $2.7 billion; year-end cash and investments guidance was raised from $4.7$5.2 billion to $8.1$8.3 billion.